Treating patients with metastatic castration resistant prostate cancer: A comprehensive review of available therapies

Journal of Urology

Volumn 194, Issue 6, 2015, Pages 1537-1547

  Crawford, E David ^a   Higano, Celestia S ^b   Shore, Neal D ^c   Hussain, Maha ^d   Petrylak, Daniel P ^e  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Atlantic Urology Clinics   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e YALE UNIVERSITY   (United States)

Author keywords

androgen antagonists; castration; drug therapy; neoplasm metastasis; prostatic neoplasms

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; CABAZITAXEL; CYTOCHROME P450 17; DOCETAXEL; ENZALUTAMIDE; RADIUM CHLORIDE RA 223; SIPULEUCEL T; TUMOR MARKER; ANDROSTANE DERIVATIVE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN; RADIOISOTOPE; RADIUM; TAXOID; TISSUE EXTRACT;

ANDROGEN SYNTHESIS; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DNA BINDING; DRUG EXPOSURE; HUMAN; METASTASIS; OVERALL SURVIVAL; PATIENT PREFERENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CANCER STAGING; DISEASE COURSE; MALE; MORTALITY; NEOPLASM METASTASIS; ORCHIECTOMY; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE;

ANDROGEN ANTAGONISTS; ANDROSTENES; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; ORCHIECTOMY; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RADIUM; SURVIVAL RATE; TAXOIDS; TISSUE EXTRACTS;

EID: 84947293379     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.06.106     Document Type: Review

References (50)

1. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (Version 2.2014). Available at http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf. Accessed June 2014.
2. J.S. de Bono, C.J. Logothetis, A. Molina, and et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995
3. H.I. Scher, K. Fizazi, F. Saad, and et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187
4. K. Fizazi, H.I. Scher, A. Molina, and et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983
5. C.J. Logothetis, E. Basch, A. Molina, and et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial Lancet Oncol 13 2012 1210
6. S. Harland, J. Staffurth, A. Molina, and et al. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy Eur J Cancer 49 2013 3648
7. C.J. Ryan, M.R. Smith, J.S. de Bono, and et al. Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138
8. D.E. Rathkopf, M.R. Smith, J.S. de Bono, and et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302) Eur Urol 66 2014 815
9. T.M. Beer, A.J. Armstrong, D.E. Rathkopf, and et al. Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 2014 424
10. C.J. Ryan, M.R. Smith, K. Fizazi, and et al. Final overall survival (OS) analysis of COU-AA-302, a randomized Phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy Ann Oncol 25 suppl. 2014 iv255
11. P.W. Kantoff, C.S. Higano, N.D. Shore, and et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411
12. J.S. de Bono, S. Oudard, M. Ozguroglu, and et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147
13. C. Parker, S. Nilsson, D. Heinrich, and et al. Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213
14. S. Nilsson, A.O. Sartor, O.S. Bruland, and et al. Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases J Clin Oncol 31 suppl. 2013 abstract 5038
15. C. Sweeney, Y.H. Chen, M.A. Carducci, and et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial J Clin Oncol 32 suppl. 2014 abstract LBA2
16. M.S. Cookson, B.J. Roth, P. Dahm, and et al. Castration-resistant prostate cancer: AUA guideline J Urol 190 2013 429
17. F. Saad, S. Hotte, C. Catton, and et al. CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update Can Urol Assoc J 7 2013 231
18. J.M. Fitzpatrick, J. Bellmunt, K. Fizazi, and et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel Eur J Cancer 50 2014 1617
19. S. Badrising, V. van der Noort, I.M. van Oort, and et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment Cancer 120 2014 968
20. F.B. Thomsen, M.A. Røder, P. Rathenborg, and et al. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate Scand J Urol 48 2014 268
21. Y. Loriot, D. Bianchini, E. Ileana, and et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol 24 2013 1807
22. K.L. Noonan, S. North, R.L. Bitting, and et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide Ann Oncol 24 2013 1802
23. D.L. Suzman, B. Luber, M.T. Schweizer, and et al. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone Prostate 74 2014 1278
24. M.D. Wissing, J.L.L.M. Coenan, P. Van den Berg, and et al. A retrospective study on cabazitaxel and abiraterone acetate sequential treatment (CAST) in docetaxel treated metastatic castrate-resistant prostate cancer patients Eur J Cancer 49 suppl. 2013 abstract 2904
25. C.J. Pezaro, A.G. Omlin, A. Altavilla, and et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents Eur Urol 66 2014 459
26. O.B. Goodman Jr., T.W. Flaig, A. Molina, and et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer Prostate Cancer Prostatic Dis 17 2014 34
27. C.J. Ryan, A. Molina, J. Li, and et al. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial J Clin Oncol 31 2013 2791
28. F. Saad, J.S. de Bono, N.D. Shore, and et al. Efficacy outcomes by baseline prostate-specific antigen (PSA): results from the phase 3 AFFIRM trial J Urol 189 suppl. 2013 abstract 785
29. J. De Bono, K. Fizazi, N. Shore, and et al. Assessing the impact of prior treatments on the efficacy of enzalutamide (ENZ): a subanalysis of the phase 3 AFFIRM trial Eur J Cancer 49 suppl. 2013 abstract 2862
30. M. Hussain, C.M. Tangen, C. Higano, and et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162) J Clin Oncol 24 2006 3984
31. O. Caffo, A. Veccia, F. Maines, and et al. Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide Future Oncol 10 2014 985
32. S. Halabi, C.Y. Lin, E.J. Small, and et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy J Natl Cancer Inst 105 2013 1729
33. E.A. Mostaghel, B.T. Marck, S.R. Plymate, and et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants Clin Cancer Res 17 2011 5913
34. J.D. Joseph, N. Lu, J. Qian, and et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509 Cancer Discov 3 2013 1020
35. Y. Li, S.C. Chan, L.J. Brand, and et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines Cancer Res 73 2013 483
36. E. Efstathiou, M. Titus, D. Tsavachidou, and et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone J Clin Oncol 30 2012 637
37. E. Efstathiou, M. Titus, S. Wen, and et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer Eur Urol 67 2014 53
38. D.S. Ricci, W. Li, T.W. Griffin, and et al. Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA-302 J Clin Oncol 32 suppl. 2014 abstract 5058
39. E.J. Small, J. Youngren, G. Thomas, and et al. Androgen receptor (AR) amplification in patients with metastatic castration-resistance prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT) J Clin Oncol 32 suppl. 2014 abstract 5020
40. A. Azad, S. Volik, A. Wyatt, and et al. Genomic analysis of circulating tumor DNA (ctDNA) in plasma of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (abi) and enzalutamide (enza) J Clin Oncol 32 suppl. 2014 abstract 5021
41. G. Attard, J.S. de Bono, W. Li, and et al. ERG rearrangements and association with clinical outcome in patients (pts) receiving abiraterone acetate (AA): Results from the COU-AA-302 study in chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) J Clin Oncol 31 suppl. 2013 abstract 5004
42. E.S. Antonarakis, C. Lu, H. Wang, and et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer N Engl J Med 371 2014 1028
43. Food and Drug Administration: Highlights of Prescribing Information. XTANDI® (enzalutamide) capsules for oral use. Initial U.S. Approval: 2012. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/203415lbl.pdf. Accessed June 2014.
44. S. Halabi, C.Y. Lin, W.K. Kelly, and et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer J Clin Oncol 32 2014 671
45. P. Ravi, J. Mateo, D. Lorente, and et al. External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone Eur Urol 66 2014 8
46. M. Afshar, F. Al-Alloosh, N.D. James, and et al. A predictive algorithm for response to abiraterone in metastatic castration relapsed prostate cancer (CRPC) J Clin Oncol 32 suppl. 2014 abstract 238
47. R. Leibowitz-Amit, A.J. Templeton, A. Omlin, and et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer Ann Oncol 25 2014 657
48. K.N. Chi, T.S. Kheoh, C.J. Ryan, and et al. A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel J Clin Oncol 31 suppl. 2013 abstract 5013
49. A. Bahl, S. Oudard, B. Tombal, and et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial Ann Oncol 24 2013 2402
50. N. Charnley, A.J. Birtle, R. Swindell, and et al. Prognostic factors for patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate prechemotherapy J Clin Oncol 32 suppl. 2014 abstract e16054